U.S. Markets open in 8 hrs 5 mins

Alimera Sciences, Inc. (ALIM)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.37-0.01 (-0.72%)
At close: 3:59PM EDT
People also watch
PSDVACRXANTHAPRIEVOK
Full screen
Previous Close1.38
Open1.36
Bid0.00 x
Ask0.00 x
Day's Range1.35 - 1.39
52 Week Range1.01 - 2.40
Volume173,883
Avg. Volume383,775
Market Cap88.92M
Beta2.79
PE Ratio (TTM)-2.75
EPS (TTM)-0.5
Earnings DateAug 1, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Trade prices are not sourced from all markets
  • Capital Cube10 days ago

    ETFs with exposure to Alimera Sciences, Inc. : June 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Alimera Sciences, Inc. Here are 5 ETFs with the largest exposure to ALIM-US. Comparing the performance and risk of Alimera Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
    Capital Cube13 days ago

    Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017

    Categories: Yahoo FinanceGet free summary analysis Alimera Sciences, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Alimera Sciences, Inc. – Ophthotech Corp., pSivida Corp., Mateon Therapeutics, Inc., Regeneron Pharmaceuticals, Inc., Insmed Incorporated, Eleven Biotherapeutics, Inc. and Aerie Pharmaceuticals, Inc. (OPHT-US, PSDV-US, MATN-US, REGN-US, INSM-US, ... Read more (Read more...)

  • Accesswire25 days ago

    Blog Coverage Eli Lilly's Late-Stage Bladder Cancer Drug CYRAMZA Meets Primary Endpoint

    Upcoming AWS Coverage on Alimera Sciences Post-Earnings Results LONDON, UK / ACCESSWIRE / June 2, 2017 / Active Wall St. blog coverage looks at the headline from Global Pharma MNC Eli Lilly And Co. (NYSE: ...